Peak protein from mutant strain w B.1.351 RBD, also commonly known as the “South African variant”. It is a full-length protein, which is active in its native trimeric form, which is stabilized in LMNG detergent.
Since the first human infection with SARS-CoV-2 described in December 2019, many subunit protein vaccines have been proposed for use in humans. Subunit vaccines use one or more suitable antigens to elicit a robust immune response. However, the main concern is the efficacy of subunit vaccines and elicited antibodies to neutralize SARS-CoV-2 variants such as B.1.1.7 (Alpha), B.1.351 (Beta), and P1 (Gamma), B.1.617 (Delta), and C.37 (Lambda). The Spike (S) protein is a potential fragment for use as an antigen in vaccine development.
This protein plays a crucial role in the first step of the infection process, as it binds to the receptor for angiotensin-converting enzyme 2 (ACE2) and enters the host cell after binding. Immunization-induced specific antibodies against the receptor-binding domain (RBD) can effectively block and prevent virus invasion. The focus of this review is the impact of the peak mutated variants of SARS-CoV2 (Alpha, Beta, Gamma, Delta and Lambda) on the efficacy of recombinant subunit vaccines. To date, little or no impact on the efficacy of the vaccine against the Alpha and Delta variants has been reported.
Such an impact on the efficacy of the vaccine for the Beta, Delta, Gamma, and Lambda variants maybe even greater compared to the Alpha variant. However, more comprehensive analyzes are needed to assess the real impact on vaccine efficacy caused by the SARS-CoV-2 variants.
R&D Systems offers a range of SARS-CoV-2 proteins and other coronavirus proteins with the same industry-leading quality specifications as our other recombinant proteins. Our SARS-CoV-2 spike proteins exhibit high-affinity binding to human ACE-2 in both ELISA and SPR. And the coronavirus proteases, papain-like protease, and 3CL protease are tested for their bioactivity using biologically relevant fluorescent substrates. For more detailed information on our recombinant coronavirus proteins, please visit the product pages listed below.